# US 2016/0355592 A1 · Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355592 A1
- Document ID: US20160355592A1
- Status: Published application
- Kind: A1
- Application number: 15/146,868
- Filed: 2016-05-04
- Published: 2016-12-08
- Earliest claimed: 2015-05-04
- Assignees: CytomX Therapeutics, Inc.
- Applicants: CytomX Therapeutics, Inc.
- Inventors: Jason Gary Sagert; Jonathan Alexander Terrett; Luc Roland Desnoyers; Shweta Singh; Annie Yang Weaver
- Web page: https://patentgrep.com/patent/US20160355592A1

## CPC

- C07K 16/2842: {against integrin beta1-subunit-containing molecules, e.g. CD29, CD49}
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68033: {the drug being a maytansine}
- A61K 47/6809: {Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 16/2839: {against the integrin superfamily}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/00: Fusion polypeptide
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates generally to antibodies that bind ITGa3, activatable antibodies that specifically bind to ITGa3 and methods of making and using these anti-ITGa3 antibodies and anti-ITGa3 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

## Claims

### Claim 1

An isolated antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3.

### Claim 2

An isolated antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3, wherein the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO: 13); a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO: 14) or WFYPESGSVKYSETFKG (SEQ ID NO: 15) or WFYPESGSVKYNEAFKG (SEQ ID NO: 16) or WFYPESGSVKYNEGFKG (SEQ ID NO: 17); a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO: 18); a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO: 21), and wherein the AB is humanized.

### Claim 3 (depends on 1)

The AB of claim 1, wherein the AB comprises:
(i) a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO: 13); a VH CDR2 comprising the amino acid sequence or WFYPESGSVKYNEGFKG (SEQ ID NO: 17); a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO: 18); a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO: 21), or
(ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11.

### Claim 4 (depends on 2)

The AB of claim 2, wherein the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11 and 12.

### Claim 5 (depends on 2)

An isolated antibody or antigen binding fragment thereof (AB), wherein the AB binds to the same epitope on human ITGa3 and/or cynomolgus monkey ITGa3 as the isolated antibody of claim 2.

### Claim 6 (depends on 2)

An isolated antibody or antigen binding fragment thereof (AB), wherein the AB cross-competes with the isolated antibody of claim 2 for binding to human ITGa3 and/or cynomolgus monkey ITGa3.

### Claim 7

(canceled)

### Claim 8

An activatable antibody that, in an activated state, binds ITGa3 comprising:
an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3;
a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state; and
a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The activatable antibody of claim 8, wherein the MM has one or more of the characteristics selected from the group consisting of:
(i) the MM has a dissociation constant for binding to the AB that is greater than the dissociation constant of the AB to ITGa3;
(ii) the MM does not interfere or compete with the AB for binding to ITGa3 when the activatable antibody is in a cleaved state;
(iii) the MM is a polypeptide of no more than 40 amino acids in length;
(iv) the MM polypeptide sequence is different from that of human ITGa3;
(v) the MM polypeptide sequence is no more than 50% identical to any natural binding partner of the AB; and
(vi) the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-54.

### Claim at position 11

-15. (canceled)

### Claim 16 (depends on 8)

The activatable antibody of claim 8, wherein the CM has one or more of the characteristics selected from the group consisting of:
(i) the CM is a substrate for a protease that is active in diseased tissue; and
(ii) the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 182-249 and 276-316.

### Claim at position 13

-18. (canceled)

### Claim 19 (depends on 8)

The activatable antibody of claim 8, wherein the antigen binding fragment thereof is selected from the group consisting of a Fab fragment, a F(ab′)2 fragment, a scFv, a scAb, a dAb, a single domain heavy chain antibody, and a single domain light chain antibody.

### Claim 20

(canceled)

### Claim 21 (depends on 8)

The activatable antibody of claim 8, wherein the AB has one or more of the characteristics selected from the group consisting of:
(i) the AB comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO: 13); a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO: 14) or WFYPESGSVKYSETFKG (SEQ ID NO: 15) or WFYPESGSVKYNEAFKG (SEQ ID NO: 16) or WFYPESGSVKYNEGFKG (SEQ ID NO: 17); a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO: 18); a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO: 21); and
(ii) the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11 and 12.

### Claim 22

(canceled)

### Claim 23 (depends on 8)

The activatable antibody of claim 8, wherein the AB is linked to the CM.

### Claim 24 (depends on 8)

The activatable antibody of claim 8, wherein the AB is linked directly to the CM.

### Claim 25 (depends on 8)

The activatable antibody of claim 8, wherein the AB is linked to the CM via a linking peptide.

### Claim 26 (depends on 8)

The activatable antibody of claim 8, wherein the MM is linked to the CM such that the activatable antibody in an uncleaved state comprises the structural arrangement from N-terminus to C-terminus as follows: MM-CM-AB or AB-CM-MM.

### Claim 27 (depends on 8)

The activatable antibody of claim 8, wherein the activatable antibody comprises a linking peptide between the MM and the CM, a linking peptide between the CM and the AB, or both a linking peptide between the MM and the CM and a linking peptide between the CM and the AB.

### Claim 28

(canceled)

### Claim 29 (depends on 8)

The activatable antibody of claim 8, wherein the activatable antibody comprises a first linking peptide (LP1) and a second linking peptide (LP2), and wherein the activatable antibody in the uncleaved state has the structural arrangement from N-terminus to C-terminus as follows: MM-LP1-CM-LP2-AB or AB-LP2-CM-LP1-MM.

### Claim 30 (depends on 29)

The activatable antibody of claim 29, wherein the two linking peptides are not identical to each other.

### Claim 31 (depends on 29)

The activatable antibody of claim 29, wherein each of LP1 and LP2 is a peptide of about 1 to 20 amino acids in length.

### Claim 32 (depends on 8)

The activatable antibody of claim 8, wherein the activatable antibody has one or more of the characteristics selected from the group consisting of:
(a) the activatable antibody comprises the heavy chain sequence of SEQ ID NO: 320 and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391;
(b) the activatable antibody comprises a combination of amino acid sequences, wherein the combination of amino acid sequences is selected from a single row in Table D, wherein for a given combination,
(i) the heavy chain of the AB comprises the amino acid sequences of the VH CDR sequences corresponding to the given combination in the single row listed in Table D,
(ii) the light chain of the AB comprises the amino acid sequences of the VL CDR sequences corresponding to the given combination in the single row listed in Table D,
(iii) the MM comprises the amino acid sequence of the mask sequence (MM) corresponding to the given combination in the single row listed in Table D, and
(iv) the CM comprises the amino acid sequence of the substrate sequence (CM) corresponding to the given combination in the single row listed in Table D;
(c) the activatable antibody comprises a combination of amino acid sequences, wherein for a given combination of amino acid sequences,
(i) the heavy chain of the AB comprises the amino acid sequences of the VII sequence or VII CDR sequences selected from the group consisting of: the VII sequence or VII CDR sequences listed in the corresponding column of Table E,
(ii) the light chain of the AB comprises the amino acid sequences of the VL sequence or VL CDR sequences selected from the group consisting of: the VL sequence or VL CDR sequences listed in the corresponding column of Table E,
(iii) the MM comprises the amino acid sequence of the mask sequence (MM) selected from the group consisting of: the MM sequences listed in the corresponding column of Table E, and
(iv) the CM comprises the amino acid sequence of the substrate sequence (CM) selected from the group consisting of: the CM sequences listed in the corresponding column of Table E; and
(d) the activatable antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 396, 398, 400, 402, 404-431, 436, 438, 440, 442, and 444-471.

### Claim at position 28

-34. (canceled)

### Claim 35

An activatable antibody comprising an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, a MM, and a CM, wherein the activatable antibody has one or more of the following characteristics selected from the group consisting of:
(i) the activatable antibody comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 320; and a light chain sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391;
(ii) the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-54, and the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 182-249 and 276-316;
(iii) the AB comprises a VII CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO: 13); a VII CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO: 14) or WFYPESGSVKYSETFKG (SEQ ID NO: 15) or WFYPESGSVKYNEAFKG (SEQ ID NO: 16) or WFYPESGSVKYNEGFKG (SEQ ID NO: 17); a VII CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO: 18); a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO: 21);
(iv) the AB comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11 and 12; and
(v) the AB comprises a VII CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO: 13); a VII CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO: 14) or WFYPESGSVKYSETFKG (SEQ ID NO: 15) or WFYPESGSVKYNEAFKG (SEQ ID NO: 16) or WFYPESGSVKYNEGFKG (SEQ ID NO: 17); a VII CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO: 18); a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO: 21), the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-54, and the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 182-249 and 276-316.

### Claim at position 30

-39. (canceled)

### Claim 40 (depends on 2)

An activatable antibody that, in an activated state, binds ITGa3 comprising:
an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds to the same epitope on human ITGa3 and/or cynomolgus monkey ITGa3 as the isolated antibody of claim 2 or wherein the AB specifically cross-competes with the isolated antibody of claim 2 for binding to human ITGa3 and/or cynomolgus monkey ITGa3;
a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state; and
a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease.

### Claim 41

(canceled)

### Claim 42 (depends on 8)

A conjugated activatable antibody comprising the activatable antibody of claim 8 conjugated to an agent.

### Claim 43 (depends on 42)

The conjugated activatable antibody of claim 42, wherein the agent has one or more of the characteristics selected from the group consisting of:
(a) the agent is a toxin or fragment thereof;
(b) the agent is a microtubule inhibitor;
(c) the agent is a nucleic acid damaging agent;
(d) the agent is a dolastatin or a derivative thereof;
(e) the agent is an auristatin or a derivative thereof;
(f) the agent is a maytansinoid or a derivative thereof;
(g) the agent is a duocarmycin or a derivative thereof;
(h) the agent is a calicheamicin or a derivative thereof;
(i) the agent is a pyrrolobenzodiazepine or a derivative thereof;
(j) the agent is auristatin E or a derivative thereof;
(k) the agent is monomethyl auristatin E (MMAE);
(l) the agent is monomethyl auristatin D (MMAD);
(m) the agent is the maytansinoid DM1;
(n) the agent is the maytansinoid DM4;
(o) the agent is a detectable moiety; and
(p) the agent is a diagnostic agent.

### Claim at position 35

-53. (canceled)

### Claim 54 (depends on 42)

The conjugated activatable antibody of claim 42, wherein the agent is conjugated to the AB via a linker.

### Claim 55 (depends on 54)

The conjugated activatable antibody of claim 54, wherein the linker with which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety,

### Claim 56 (depends on 42)

The conjugated activatable antibody of claim 42, wherein the agent is a toxin conjugated to the AB via a linker, and wherein the linker and the toxin conjugated to the AB comprise a moiety selected from the group consisting of: an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety,

### Claim 57 (depends on 54)

The conjugated activatable antibody of claim 54, wherein the linker is a cleavable linker.

### Claim 58 (depends on 54)

The conjugated activatable antibody of claim 54, wherein the linker is a non-cleavable linker.

### Claim at position 41

-60. (canceled)

### Claim 61

A conjugated activatable antibody that, in an activated state, binds ITGa3 comprising:
(a) an activatable antibody comprising:
(i) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3;
(ii) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state; and
(iii) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease; and
(b) an agent conjugated to the AB.

### Claim 62 (depends on 61)

The conjugated activatable antibody of claim 61, wherein the agent is selected from the group consisting of a dolastatin or a derivative thereof, an auristatin or a derivative thereof, a maytansinoid or a derivative thereof, a duocarmycin or a derivative thereof, a calicheamicin or a derivative thereof, a pyrrolobenzodiazepine or a derivative thereof, auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a duocarmycin, a calicheamicin, a pyrrolobenzodiazepine, and a pyrrolobenzodiazepine dimer.

### Claim 63

(canceled)

### Claim 64 (depends on 61)

The conjugated activatable antibody of claim 61, wherein the agent is conjugated to the AB via a linker.

### Claim 65 (depends on 64)

The conjugated activatable antibody of claim 64, wherein the linker with which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety,

### Claim 66 (depends on 61)

The conjugated activatable antibody of claim 61, wherein the agent is a toxin conjugated to the AB via a linker, and wherein the linker and the toxin conjugated to the AB comprise a moiety selected from the group consisting of: an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety,

### Claim 67 (depends on 61)

The conjugated activatable antibody of claim 61, wherein the activatable antibody has one or more of the characteristics selected from the group consisting of:
(i) the activatable antibody comprises a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO: 13); a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO: 14) or WFYPESGSVKYSETFKG (SEQ ID NO: 15) or WFYPESGSVKYNEAFKG (SEQ ID NO: 16) or WFYPESGSVKYNEGFKG (SEQ ID NO: 17); a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO: 18); a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO: 21);
(ii) the activatable antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 396, 398, 400, 402, 404-431, 436, 438, 440, 442, and 444-471; and
(iii) the activatable antibody comprises a heavy chain comprising an amino acid sequence of SEQ ID NO: 320; and a light chain sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391.

### Claim 68

(canceled)

### Claim 69 (depends on 61)

The conjugated activatable antibody of claim 61, wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-54.

### Claim 70

(canceled)

### Claim 71 (depends on 61)

The conjugated activatable antibody of claim 61, wherein the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 182-249 and 276-316.

### Claim 72

(canceled)

### Claim 73 (depends on 61)

The conjugated activatable antibody of claim 61, wherein the activatable antibody has one or more of the following characteristics selected from the group consisting of:
(i) the activatable antibody comprises a combination of amino acid sequences, wherein the combination of amino acid sequences is selected from a single row in Table D,
wherein for a given combination,
(a) the heavy chain of the AB comprises the amino acid sequences of the VH CDR sequences corresponding to the given combination in the single row listed in Table D,
(b) the light chain of the AB comprises the amino acid sequences of the VL CDR sequences corresponding to the given combination in the single row listed in Table D,
(c) the MM comprises the amino acid sequence of the mask sequence (MM) corresponding to the given combination in the single row listed in Table D, and
(d) the CM comprises the amino acid sequence of the substrate sequence (CM) corresponding to the given combination in the single row listed in Table D; and
(ii) the activatable antibody comprises a combination of amino acid sequences, wherein for a given combination of amino acid sequences,
(a) the heavy chain of the AB comprises the amino acid sequences of the VII sequence or VII CDR sequences selected from the group consisting of: the VII sequence or VII CDR sequences listed in the corresponding column of Table E,
(b) the light chain of the AB comprises the amino acid sequences of the VL sequence or VL CDR sequences selected from the group consisting of: the VL sequence or VL CDR sequences listed in the corresponding column of Table E,
(c) the MM comprises the amino acid sequence of the mask sequence (MM) selected from the group consisting of: the MM sequences listed in the corresponding column of Table E, and
(d) the CM comprises the amino acid sequence of the substrate sequence (CM) selected from the group consisting of: the CM sequences listed in the corresponding column of Table E.

### Claim at position 55

-75. (canceled)

### Claim 76

A conjugated antibody comprising:
(a) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB comprises:
(i) a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO: 13); a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO: 14) or WFYPESGSVKYSETFKG (SEQ ID NO: 15) or WFYPESGSVKYNEAFKG (SEQ ID NO: 16) or WFYPESGSVKYNEGFKG (SEQ ID NO: 17); a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO: 18); a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO: 21), or
(ii) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11 and 12; or
(iii) a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 320, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 322; and
(b) an agent conjugated to the AB, wherein the agent is selected from the group consisting of auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a calicheamicin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, and a duocarmycin.

### Claim 77

A conjugated activatable antibody that, in an activated state, binds to ITGa3, comprising:
(a) an activatable antibody comprising:
(i) an antibody or an antigen binding fragment thereof (AB) that specifically binds to mammalian ITGa3, wherein the AB specifically binds human ITGa3 and cynomolgus monkey ITGa3;
(ii) a masking moiety (MM) coupled to the AB that inhibits the binding of the AB to ITGa3 when the activatable antibody is in an uncleaved state;
(iii) a cleavable moiety (CM) coupled to the AB, wherein the CM is a polypeptide that functions as a substrate for a protease; and
(b) an agent conjugated to the AB,
wherein the activatable antibody comprises:
(i) a VH CDR1 comprising the amino acid sequence EYIIH (SEQ ID NO: 13); a VH CDR2 comprising the amino acid sequence WFYPESGSVKYNETFKG (SEQ ID NO: 14) or WFYPESGSVKYSETFKG (SEQ ID NO: 15) or WFYPESGSVKYNEAFKG (SEQ ID NO: 16) or WFYPESGSVKYNEGFKG (SEQ ID NO: 17); a VH CDR3 comprising the amino acid sequence HEERDYYGYYAMDY (SEQ ID NO: 18); a VL CDR1 comprising the amino acid sequence SASSSISSNYLH (SEQ ID NO: 19); a VL CDR2 comprising the amino acid sequence RTSNLA (SEQ ID NO: 20); and a VL CDR3 comprising the amino acid sequence QQGSSIPRFT (SEQ ID NO: 21), or
(ii) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-10, and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 11, 12, 396, 398, 400, 402, 404-431, 436, 438, 440, 442, and 444-471; or
(iii) a heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 320, and a light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 255, 257, 259, 261, 322, 324, 326, 328, 330, 332-359, and 364-391; and
wherein the agent is selected from the group consisting of auristatin E, monomethyl auristatin F (MMAF), monomethyl auristatin E (MMAE), monomethyl auristatin D (MMAD), maytansinoid DM4, maytansinoid DM1, a calicheamicin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, and a duocarmycin.

### Claim 78 (depends on 77)

The conjugated activatable antibody of claim 77, wherein the MM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 22-54.

### Claim 79

(canceled)

### Claim 80 (depends on 77)

The conjugated activatable antibody of claim 77, wherein the CM comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 182-249 and 276-316.

### Claim 81

(canceled)

### Claim 82 (depends on 77)

The conjugated activatable antibody of claim 77 wherein the agent is conjugated to the AB via a linker, and wherein the linker to which the agent is conjugated to the AB comprises an SPDB moiety, a vc moiety, or a PEG2-vc moiety,

### Claim 83 (depends on 77)

The conjugated antibody or conjugated activatable antibody of claim 77, wherein the linker and toxin conjugated to the AB comprises an SPDB-DM4 moiety, a vc-MMAD moiety, a vc-MMAE moiety, a vc-duocarmycin moiety, or a PEG2-vc-MMAD moiety,

### Claim 84

A conjugated activatable antibody or conjugated antibody comprising:
an antibody or antigen binding fragment thereof (AB) that, in an activated state, binds ITGa3; and
a toxin conjugated to the AB via a linker,
wherein the conjugated activatable antibody or the conjugated antibody comprises amino acid sequences, a linker, and a toxin selected from a single row in Table F, wherein for the given combination:
(a) the AB comprises a heavy chain comprising the amino acid sequence of the heavy chain sequence or heavy chain variable domain sequence corresponding to the given combination in the single row listed in Table F,
(b) the AB comprises a light chain comprising the amino acid sequence of the light chain sequence or light chain variable domain sequence corresponding to the given combination in the single row listed in Table F, and
(c) the linker and the toxin comprise the linker and the toxin corresponding to the given combination in the single row listed in Table F.

### Claim 85 (depends on 8)

A pharmaceutical composition comprising the activatable antibody of claim 8 and a carrier.

### Claim 86 (depends on 85)

The pharmaceutical composition of claim 85 comprising an additional agent.

### Claim 87 (depends on 86)

The pharmaceutical composition of claim 86, wherein the additional agent is a therapeutic agent.

### Claim 88 (depends on 8)

An isolated nucleic acid molecule encoding the activatable antibody of claim 8.

### Claim 89 (depends on 88)

A vector comprising the isolated nucleic acid molecule of claim 88.

### Claim 90 (depends on 88)

A method of producing an activatable antibody by culturing a cell under conditions that lead to expression of the activatable antibody, wherein the cell comprises the nucleic acid molecule of claim 88.

### Claim 91 (depends on 8)

A method of manufacturing an activatable antibody that, in an activated state, binds ITGa3, the method comprising:
(a) culturing a cell comprising a nucleic acid construct that encodes the activatable antibody under conditions that lead to expression of the activatable antibody, wherein the activatable antibody comprises activatable antibody of claim 8;
and
(b) recovering the activatable antibody.

### Claim 92 (depends on 42)

A method of treating, alleviating a symptom of, or delaying the progression of a disorder or disease in which diseased cells express ITGa3 comprising administering a therapeutically effective amount of the conjugated activatable antibody of claim 42 to a subject in need thereof.

### Claim 93 (depends on 92)

The method of claim 92, wherein the disorder or disease is cancer.

### Claim 94 (depends on 42)

A method of treating, alleviating a symptom of, or delaying the progression of a disorder or disease associated with cells expressing ITGa3 comprising administering a therapeutically effective amount of the conjugated activatable antibody of claim 42 to a subject in need thereof.

### Claim 95 (depends on 94)

The method of claim 94, wherein the disorder or disease associated with cells expressing ITGa3 is cancer.

### Claim 96 (depends on 95)

The method of claim 95, wherein the cancer is an adenocarcinoma, a bile duct (biliary) cancer, a bladder cancer, a bone cancer, a breast cancer, a Her2-negative breast cancer, a triple-negative breast cancer, an endometrial cancer, an estrogen receptor-positive breast cancer, a carcinoid, a cervical cancer, a cholangiocarcinoma, a colorectal cancer, a colon cancer, an endometrial cancer, a glioma, a head and neck cancer, a head and neck squamous cell cancer, a leukemia, a liver cancer, a lung cancer, a non-small cell lung cancer, a small cell lung cancer, a lymphoma, a melanoma, an oropharyngeal cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a metastatic castration-resistant prostate carcinoma, a renal cancer, a sarcoma, a skin cancer, a squamous cell cancer, a stomach cancer, a testis cancer, a thyroid cancer, a urogenital cancer, or a urothelial cancer.

### Claim 97 (depends on 42)

A method of inhibiting or reducing the growth, proliferation, or metastasis of cells expressing mammalian ITGa3 comprising administering a therapeutically effective amount of the conjugated activatable antibody of claim 42 to a subject in need thereof.

### Claim 98 (depends on 8)

A method of inhibiting, blocking, or preventing the binding of a natural ligand or receptor to mammalian ITGa3, comprising administering a therapeutically effective amount of the activatable antibody of claim 8 to a subject in need thereof.

### Claim 99 (depends on 92)

The method of claim 92, wherein the method comprises administering an additional agent.

### Claim 100 (depends on 99)

The method of claim 99, wherein the additional agent is a therapeutic agent.

### Claim 101 (depends on 97)

The method of claim 97 wherein the expression and/or activity of the mammalian ITGa3 is aberrant.

### Claim 102 (depends on 42)

A pharmaceutical composition comprising the conjugated activatable antibody of claim 42; and a carrier.

### Claim 103 (depends on 102)

The pharmaceutical composition of claim 102 comprising an additional agent.

### Claim 104 (depends on 93)

The method of claim 93, wherein the cancer is an adenocarcinoma, a bile duct (biliary) cancer, a bladder cancer, a bone cancer, a breast cancer, a triple-negative breast cancer, a Her2-negative breast cancer, a carcinoid cancer, a cervical cancer, a cholangiocarcinoma, a colorectal cancer, a colon cancer, an endometrial cancer, a glioma, a head and neck cancer, a head and neck squamous cell cancer, a leukemia, a liver cancer, a lung cancer, a non-small cell lung cancer, a small cell lung cancer, a lymphoma, a melanoma, an oropharyngeal cancer, an ovarian cancer, a pancreatic cancer, a prostate cancer, a metastatic castration-resistant prostate carcinoma, a renal cancer, a sarcoma, a skin cancer, a squamous cell cancer, a stomach cancer, a testis cancer, a thyroid cancer, a urogenital cancer, or a urothelial cancer.

### Claim 105 (depends on 8)

The activatable antibody of claim 8, wherein the MM is linked to the CM.

### Claim 106 (depends on 8)

The activatable antibody of claim 8, wherein the MM is linked directly to the CM.

### Claim 107 (depends on 8)

The activatable antibody of claim 8, wherein the MM is linked to the CM via a linking peptide.
